- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02077179
Health Improvement After Pregnancy (HIP) Program Randomized Control Trial (HIP)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- Queen's Unviersity
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- must own or have daily access to one or more of the following; smart phone, tablet or laptop computer
Exclusion Criteria:
- Living greater than 100km from Kingston General Hospital
- Having an existing and long term contraindication to exercise at the time of recruitment
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Nessun intervento: Standard of Care
Participants in this arm will receive care as per the usual standards from Kingston General Hospital and their primary care provider.
|
|
|
Sperimentale: HIP Program
Participants in this arm will follow the HIP Program in addition to their usual care from Kingston General Hospital and their primary care provider.
|
The entirety of the HIP Program is delivered through an interactive mobile website. The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment. The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Metabolic Syndrome Z Score
Lasso di tempo: 32 weeks postpartum
|
The primary outcome measure is the metabolic syndrome (MetS) z score, a continuous score of the five metabolic syndrome variables that make up the Adult Treatment Panel (ATP) III diagnostic criteria (waist circumference, blood pressure, high density lipoprotein, triglycerides and glucose).
Differences between study arms will be compared.
|
32 weeks postpartum
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Adherence to the HIP Program; Percent of Workouts Completed
Lasso di tempo: 32 weeks postpartum
|
Adherence to the HIP Program will be assessed based on the number of times a participant indicates using the mobile website that a prescribed workout has been completed.
This outcome will only be measured in the intervention arm.
|
32 weeks postpartum
|
|
Differences in Biochemical Cardiovascular Risk Markers
Lasso di tempo: 32 weeks postpartum
|
Differences between study arms for the following biochemical cardiovascular risk markers will be assessed at 32 weeks postpartum; lipid profile, fasting glucose, glycated hemoglobin, high sensitivity C-reactive protein, and urine microalbumin creatinine ratio.
|
32 weeks postpartum
|
|
Change in Anthropomorphic Measurements and Blood Pressure from Baseline at Midpoint
Lasso di tempo: 20 weeks postpartum
|
Changes in systolic blood pressure, diastolic blood pressure and weight from baseline measures at 6-8 weeks postpartum will be assessed at the midpoint of the program at 20 weeks postpartum.
Differences between study arms will be compared.
|
20 weeks postpartum
|
|
Change in Anthropomorphic Measurements and Blood Pressure from Baseline at Study Completion
Lasso di tempo: 32 weeks postpartum
|
Changes in systolic blood pressure, diastolic blood pressure and weight from baseline measures at 6-8 weeks postpartum will be assessed at the midpoint of the program at 32 weeks postpartum.
Differences between study arms will be compared.
|
32 weeks postpartum
|
|
Change in Anthropomorphic Measurements and Blood Pressure from Midpoint to Study Completion
Lasso di tempo: 32 weeks postpartum
|
Changes in systolic blood pressure, diastolic blood pressure, weight, body mass index, hip circumference, and waist circumference from midpoint measures at 20 weeks postpartum will be assessed at the end of the program at 32 weeks postpartum.
Differences between study arms will be compared.
|
32 weeks postpartum
|
|
Adherence to the HIP Program; Percent of Step Counting Completed
Lasso di tempo: 32 weeks postpartum
|
Adherence to the HIP Program will be assessed based on the number of times a participant uses the mobile website to log their daily step count total.
The number of times that the logged step count meets or exceeds the prescribed number of daily steps will also be assessed.
This outcome will only be measured in the intervention arm.
|
32 weeks postpartum
|
|
Adherence to the HIP Program; Percent of Dietary Logs Completed
Lasso di tempo: 32 weeks postpartum
|
Adherence to the HIP Program will be assessed based on the number of times a participant uses the mobile website to enter the weekly dietary log.
The number of times that the dietary log meets the prescribed intake for each of the Canada's Food Guide food groups will also be assessed.
This outcome will only be measured in the intervention arm.
|
32 weeks postpartum
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Graeme N Smith, MD,PhD,FRCSC, Queen's University
Pubblicazioni e link utili
Pubblicazioni generali
- Smith GN, Pudwell J, Roddy M. The Maternal Health Clinic: a new window of opportunity for early heart disease risk screening and intervention for women with pregnancy complications. J Obstet Gynaecol Can. 2013 Sep;35(9):831-839. doi: 10.1016/S1701-2163(15)30841-0. No abstract available.
- Cusimano MC, Pudwell J, Roddy M, Cho CK, Smith GN. The maternal health clinic: an initiative for cardiovascular risk identification in women with pregnancy-related complications. Am J Obstet Gynecol. 2014 May;210(5):438.e1-9. doi: 10.1016/j.ajog.2013.12.001. Epub 2013 Dec 4.
- Smith GN, Pudwell J, Walker M, Wen SW. Risk estimation of metabolic syndrome at one and three years after a pregnancy complicated by preeclampsia. J Obstet Gynaecol Can. 2012 Sep;34(9):836-841. doi: 10.1016/S1701-2163(16)35382-8.
- Smith GN, Pudwell J, Walker M, Wen SW. Ten-year, thirty-year, and lifetime cardiovascular disease risk estimates following a pregnancy complicated by preeclampsia. J Obstet Gynaecol Can. 2012 Sep;34(9):830-835. doi: 10.1016/S1701-2163(16)35381-6.
- Smith GN, Walker MC, Liu A, Wen SW, Swansburg M, Ramshaw H, White RR, Roddy M, Hladunewich M; Pre-Eclampsia New Emerging Team (PE-NET). A history of preeclampsia identifies women who have underlying cardiovascular risk factors. Am J Obstet Gynecol. 2009 Jan;200(1):58.e1-8. doi: 10.1016/j.ajog.2008.06.035. Epub 2008 Aug 8.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- OBGY-249-14
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .